-+ 0.00%
-+ 0.00%
-+ 0.00%

Pasithea Adds Drug Expert Dr. James Lee To Guide New Treatment For Crohn's And Other Inflammatory Diseases

Benzinga·06/11/2025 11:22:07
Listen to the news

Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, primary sclerosing cholangitis and ankylosing spondylitis.